Enzymatica strengthens its presence in the UK through collaboration with the Lloyds pharmacy chain
the Lloyds pharmacy chain to sell the common cold product ColdZyme® in the UK.
The agreement means that this winter ColdZyme will be available in about 1 300
Lloyds pharmacies. The product launch is planned for December 2015.
Enzymatica, through its partner AHA Worldwide Ltd, has signed an agreement with the Lloyds pharmacy chain to sell the common cold product ColdZyme® in the UK. The agreement means that this winter ColdZyme will be available in about 1 300 Lloyds pharmacies. The product launch is planned for December 2015.
The partnership initially covers the smaller package size ColdZyme OneCold 7 ml, which is a key entry product for new customers. After a short evaluation phase, the larger size of the product will also be considered for launch.
"In accordance with our strategy, we are introducing ColdZyme into another British pharmacy chain in order to reach more consumers and strengthen our presence in the important UK market. Through the partnership with Lloyds we are almost doubling the number of outlets in the UK, which should increase interest in the product from both consumers and potential distributors. Our intention is to find a partner to take responsibility for the entire supply chain, including market investment," says Fredrik Lindberg, CEO of Enzymatica.
Lloyd's is a leading pharmacy chain with a high patient self-care focus and a total of about 1 600 pharmacies in the UK.
Since autumn 2014 ColdZyme has been sold to Boots pharmacies in the UK via the contracts organization AHA Worldwide Ltd. Within the EU, the UK is one of the five largest markets for OTC cold and flu products. In 2012 the value of the category was around USD 945 million.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Phone: +46 708-86 53 70 | E-mail: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on four markets. The product became the leading article for colds in Swedish pharmacies in winter 2014-2015. Development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The company is headquartered in Lund, Sweden and has been listed on Nasdaq First North since June 2015. For more information, please visit www.enzymatica.com.
Erik Penser Bankaktiebolag is Certified Adviser for Enzymatica.
For more information, please visit: www.lloydspharmacy.com.